Abingdon, UK, 13th January 2020. OBS Medical limited, is pleased to celebrate the announcement of its partnership with Qardio to launch QardioMD+VSI.
QardioMD+VSI is a remote monitoring solution that combines the data from Qardio’s range of award winning and medically accurate wearables, with the Visensia® predictive algorithm. This combination allows Clinicians to remotely review a patients’ vital signs in real time and to prioritise those patients according to the Visensia risk stratification algorithm – Visensia Safety Index (VSI).
Mark Prince, CEO, Qardio said: “The QardioMD platform has been developed to remotely collect and present multiple key vital signs. With the addition of the Visensia Safety Index, the power of Qardio’s suite of remote patient monitoring solutions is extended to include a predictive capability – a critical advantage to care providers and their patients, at a time when in-clinic visits present added risk or may not be practical.”
“The option to track patient trends, with a predictive score, enables care providers to remain engaged, particularly with at-risk patient populations, under all conditions. QardioMD+VSI eliminates gaps presented by distance, restrictions, or capacity constraints – and positions care providers to make informed decisions”.
Simon Didcote, CEO, OBS Medical said: “We believe that this partnership is unique in its offering to care providers. It bridges the gap that has eluded so many wanting a remote monitoring solution that spans the continuum of care from hospital to home. The combination of continuous vital sign data and predictive analytics, allows for the earlier detection of instability and intervention, helping to improve outcomes for the patient and for the provider.”
“Visensia’s predictive Safety Index algorithm depends on high quality, continuous patient data collection, and I’m pleased to partner with Qardio to offer customers this fully integrated solution to help in today’s current crisis, but also to cement the use of remote patient monitoring such as QardioMD + VSI as part of mainstream care provision”.
QardioMD+VSI enables doctors to monitor a patient’s condition using data such as heart rate, respiratory rate, temperature, and blood pressure, all recorded remotely via QardioCore, QardioArm, and other compatible devices.
The VSI provides an aggregate score based on three or more of Qardio monitored vital signs. The VSI understands the correlation between vital signs and provides Clinicians with a single numerical index that represents the patients’ overall wellness. It has been clinically proven to provide over 6hrs advanced warning of critical instability when compared to standard methods currently used.
For more information, visit www.getqardio.com/qardiomd-vsi/
Qardio is a health technology company that operates at the intersection of cardiology, remote monitoring, and medical SaaS. Qardio’s suite of remote monitoring solutions provide improved outcomes for care providers and their patients via improved workflows and diagnostic yields, reduced cost, and ease of use.
Founded in 2012, Qardio’s primary mission is to improve outcomes for adults living with a chronic heart condition through simplified diagnosis and monitoring. Our products include QardioCore, a unique ambulatory ECG, QardioArm, a smart blood pressure monitor, and QardioBase, a smart scale and body composition monitor – all enabled by the Qardio App. Our award winning solutions are available via traditional medical channels as well as consumer channels, in order to deliver the greatest impact.
More information is available at www.qardiomd.com
For press enquiries please contact Charlie Monger on Charlie@getqardio.com
Tel: UK +44 (0) 7852233947